Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell
lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …

Background The EGFR T790M mutation is the most common mechanism of drug resistance
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …

Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in …

Background No therapies for targeting KRAS mutations in cancer have been approved. The
KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to …

Background Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …

Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …

Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …

BACKGROUND Monoclonal antibodies against programmed cell death protein 1 (PD‐1) and
programmed death ligand 1 (PD‐L1) are effective therapies in patients with non‐small cell …